Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1Phase 2 1Phase 1/2 1

Status

Completed 2Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 1Gynecologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Polycystic Ovary Syndrome 1Lymphoma, Follicular 1Hypertension 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 2042Radiotherapy 1859Cisplatin 1825Carboplatin 1533Gemcitabine 1434Paclitaxel 1289Bevacizumab 1270Docetaxel 1202pembrolizumab 1199Oxaliplatin 1160Capecitabine 1144Fluorouracil 1061Dexamethasone 971Rituximab 919Nivolumab 908Magnetic Resonance Spectroscopy 862Etoposide 839Doxorubicin 823Drug Therapy 792Radiosurgery 776Irinotecan 775Cytarabine 736fludarabine 716Leucovorin 676Lenalidomide 608fludarabine phosphate 564Temozolomide 552Radiation 541Filgrastim 540Cetuximab 537

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Interventional × Amlodipine × Clear all
NCT06942377 2025-07-08

Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy

Peking University People's Hospital

Phase 2 Not yet recruiting
140 enrolled
Gynecologic

Endometrial Neoplasms

NCT02834403 2023-12-15

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

The Methodist Hospital Research Institute

Phase 1/2 Completed
37 enrolled 20 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02544776 2016-03-25

Amlodipine on Blood Flow of Preovulatory Follicle in Polycystic Ovarian Patients

Ain Shams Maternity Hospital

Phase NA Completed
60 enrolled

Polycystic Ovary Syndrome

NCT01048047 2010-01-13

Effects of Aliskiren/Amlodipine Versus Amlodipine Monotherapy on Ankle-foot Volume in Hypertensive Patients

University of Pavia

Phase 4 Unknown
88 enrolled
Lymphoid

Hypertension, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡